What do systematic reviews say?

Summary of findings: Iron vs placebo or usual care

Summary of findings: Iron showed no clear difference in death (all causes) compared with placebo/usual care (low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.52 [0.06, 4.65]
  2 studies · 239 participants
  Low

Summary of findings: Iron vs placebo or usual care

The review found no eligible studies for this question.

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Iron vs placebo or usual care

The review found no eligible studies for this question.

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Iron vs placebo or usual care

It is very uncertain whether summary of findings: Iron changes nausea compared with placebo/usual care (very low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.99 [0.3, 3.27]
  1 study · 149 participants
  Very low

Summary of findings: Iron vs placebo or usual care

The review found no eligible studies for this question.

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Iron vs placebo or usual care

Summary of findings: Iron probably leads to higher constipation compared with placebo/usual care (moderate certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 2.66 [1.15, 6.12]
  3 studies · 422 participants
  Moderate

Summary of findings: Iron vs placebo or usual care

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 422 participants
  Low

Summary of findings: Iron vs placebo or usual care

The review found no eligible studies for this question.

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 612 participants
  Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 390 participants
  Low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 452 participants
  Very low

Medication management vs usual care

The review found no eligible studies for this question.

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Very low

DFX film‐coated tablet vs DFX dispersible tablet

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

DFP and DFO vs DFP

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 369 participants
  Low

DFP and DFO vs deferoxamine

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 281 participants
  Low

DFP and DFO vs DFP and DFX

Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  RR 0.84 [0.72, 0.99]
  1 study · 96 participants
  Low

Summary of findings: lipid‐based nutrient supplements (LNS) vs iron folic acid (IFA)

• Lipid‐based nutrient supplements for maternal, birth, and infant developmental outcomes 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 3539 participants
  Moderate

Summary of findings: lipid‐based nutrient supplements (LNS) vs iron folic acid (IFA)

Summary of findings: lipid‐based nutrient supplements (LNS) probably leads to higher maternal anaemia at term or near term (haemoglobin (Hb) less than… compared with iron folic acid (IFA) (moderate certainty).

• Lipid‐based nutrient supplements for maternal, birth, and infant developmental outcomes 2018 · Cochrane Headline outcomes only
  RR 2.35 [1.67, 3.3]
  1 study · 536 participants
  Moderate

Summary of findings: lipid‐based nutrient supplements (LNS) vs iron folic acid (IFA)

Summary of findings: lipid‐based nutrient supplements (LNS) showed no clear difference in maternal mortality (measured at six weeks postpartum) compared with iron folic acid (IFA) (moderate certainty).

• Lipid‐based nutrient supplements for maternal, birth, and infant developmental outcomes 2018 · Cochrane Headline outcomes only
  RR 0.53 [0.12, 2.41]
  3 studies · 5628 participants
  Moderate